Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;6(1):15-9.
doi: 10.1177/2042098614560736.

New antiepileptic medication linked to blue discoloration of the skin and eyes

Sarah Clark  1 , Alexandra Antell  2 , Kimberly Kaufman  3
Affiliations
Review

New antiepileptic medication linked to blue discoloration of the skin and eyes

Sarah Clark et al. Ther Adv Drug Saf. 2015 Feb.

Abstract

Ezogabine is an antiepileptic medication approved in June 2011 by the US Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures. Minimal drug interactions and a novel mechanism of action made ezogabine an appealing new treatment option. However, adverse effects reported during clinical trials and following drug approval have been alarming. A Risk Evaluation Mitigation Strategy (REMS) program has been established for urinary retention. A safety alert was published in April 2013 warning ezogabine may cause retinal pigment abnormalities and/or blue-gray discoloration, most notably on or near the lips, nail beds, sclera and conjunctiva with long-term use. In October 2013, the FDA announced a formal label change to ezogabine to include a black boxed warning emphasizing the previously reported warnings of eye and skin discoloration and permanent vision changes. Given the unknown nature of the pathophysiology, consequences and potential for reversibility of these effects, GlaxoSmithKline and the FDA have published recommendations for patients currently receiving ezogabine. Further data from published case reports and long-term safety trials in the future may lend additional insight into these concerning effects.

Keywords: antiepilepsy medication; ezogabine; seizure; skin discoloration.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Afeli S., Malysz J., Petkov G. (2013) Molecular expression and pharmacological evidence for a functional role of kv7 channel subtypes in guinea pig urinary bladder smooth muscle. PloS One 8: e75875. - PMC - PubMed
    1. Ammann R., Braathen L. (1996) [Amiodarone pigmentation]. Hautarzt 47: 930–931. - PubMed
    1. Berg A., Berkovic S., Brodie M., Buchhalter J., Cross J., Van Emde Boas W., et al. (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51: 676–685. - PubMed
    1. Biton V., Gil-Nagel A., Brodie M., Derossett S., Nohria V. (2013) Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures. Epilepsy Res 107: 138–145. - PubMed
    1. Blume W., Luders H., Mizrahi E., Tassinari C., Van Emde Boas W., Engel J., Jr. (2001) Glossary of descriptive terminology for ictal semiology: report of the ILAE Task Force on Classification and Terminology. Epilepsia 42: 1212–1218. - PubMed

LinkOut - more resources

-